A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer
To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Naproxen-n-butyl nitrate
- drug : Calcitriol
Phase: Phase 2
Ages Eligible For Study:
- Must give written informed consent - Histologically confirmed adenocarcinoma of the prostate - Biochemical relapse after primary radiation therapy or surgery - Normal testosterone levels - 3 rising PSA after nadir, with interval between PSA determinations > 2 weeks